Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia 21-09-2024, 15:15

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation 17-12-2024, 13:00

First Solar, Inc. to Announce Fourth Quarter and Full Year 14-02-2023, 21:07